Safety and Immunogenicity of Pneumococcal Protein Vaccine (PPrV) in Healthy Adults, Toddlers and Infants in Bangladesh

Trial Profile

Safety and Immunogenicity of Pneumococcal Protein Vaccine (PPrV) in Healthy Adults, Toddlers and Infants in Bangladesh

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2014

At a glance

  • Drugs Pneumococcal vaccine (Primary) ; Aluminium hydroxide
  • Indications Pneumococcal infections
  • Focus Adverse reactions
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 02 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov (NCT01446926).
    • 02 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov (NCT01446926).
    • 12 Nov 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov (NCT01764126).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top